FDA approves Brintellix from Lundbeck, Takeda

FDA approved an NDA from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for Brintellix vortioxetine to treat major depressive disorder (MDD). Takeda and partner H. Lundbeck A/S (CSE:LUN) plan to launch t...